These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6889435)

  • 41. Operant control of turning in circles: a new model of dopaminergic drug action.
    Glick SD
    Brain Res; 1982 Aug; 245(2):394-7. PubMed ID: 6889903
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced dopamine metabolism in accumbens leads to motor activity and concurrently to increased output from nondopamine neurons in ventral tegmental area and substantia nigra.
    Olds ME
    Physiol Behav; 1992 Jan; 51(1):39-50. PubMed ID: 1311110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On the role of ascending catecholaminergic projections in intracranial self-stimulation of the substantia nigra.
    Clavier RM; Fibiger HC
    Brain Res; 1977 Aug; 131(2):271-86. PubMed ID: 890458
    [No Abstract]   [Full Text] [Related]  

  • 44. Kindling of dopaminergic pathways modifies the effect of substantia nigra lesions on rotational behaviour.
    Mintz M; Herberg LJ
    Neurosci Lett; 1985 Oct; 61(1-2):7-11. PubMed ID: 3001593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence that the nigrotegmental GABAergic projection mediates stereotypy induced by apomorphine and intranigral muscimol.
    Childs JA; Gale K
    Life Sci; 1983 Sep; 33(10):1007-10. PubMed ID: 6684199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopamine and norepinephrine levels in the nucleus accumbens, olfactory tubercle and corpus striatum following lesions in the ventral tegmentalarea.
    Koob GF; Balcom GJ; Meyerhoff JL
    Brain Res; 1975 Aug; 94(1):45-55. PubMed ID: 1148866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for a role of endogenous opioids in the nigrostriatal system: influence of naloxone and morphine on nigrostriatal dopaminergic supersensitivity.
    Hirschhorn ID; Hittner D; Gardner EL; Cubells J; Makman MH
    Brain Res; 1983 Jun; 270(1):109-17. PubMed ID: 6409355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterogeneity of electrically evoked dopamine release and reuptake in substantia nigra, ventral tegmental area, and striatum.
    Cragg S; Rice ME; Greenfield SA
    J Neurophysiol; 1997 Feb; 77(2):863-73. PubMed ID: 9065855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons.
    Di Chiara G; Porceddu ML; Morelli M; Mulas ML; Gessa GL
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Mar; 306(2):153-9. PubMed ID: 571967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amphetamine-like stimulus properties produced by electrical stimulation of reward sites in the ventral tegmental area.
    Druhan JP; Fibiger HC; Phillips AG
    Behav Brain Res; 1990 May; 38(2):175-84. PubMed ID: 2163647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Motivational versus motor impairment after haloperidol injection or 6-OHDA lesions in the ventral tegmental area or substantia nigra in rats.
    Papp M; Bal A
    Physiol Behav; 1986; 38(6):773-9. PubMed ID: 3103150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of microinjections of amphetamine into the neostriatum and the nucleus accumbens on self-stimulation behaviour.
    Broekkamp CL; Pijnenburg AJ; Cools AR; Van Rossum JM
    Psychopharmacologia; 1975 May; 42(2):179-83. PubMed ID: 1161977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 54. Protection against dopaminergic nigrostriatal cell death by excitatory input ablation.
    Takada M; Matsumura M; Kojima J; Yamaji Y; Inase M; Tokuno H; Nambu A; Imai H
    Eur J Neurosci; 2000 May; 12(5):1771-80. PubMed ID: 10792454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

  • 56. An examination of parkinsonian versus anhedonia contributions to self-stimulation impairments induced by dopamine dysfunction.
    Carey RJ
    Behav Brain Res; 1986 Nov; 22(2):117-25. PubMed ID: 3024663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions.
    Slater P; Crossman AR
    Neuropharmacology; 1980 Mar; 19(3):289-95. PubMed ID: 7191487
    [No Abstract]   [Full Text] [Related]  

  • 58. Intrastriatal dopaminergic grafts restore inhibitory control over striatal cholinergic neurons.
    Herman JP; Lupp A; Abrous N; Le Moal M; Hertting G; Jackisch R
    Exp Brain Res; 1988; 73(2):236-48. PubMed ID: 3145893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amphetamine-induced rotation reveals post 6-OHDA lesion neurochemical reorganization.
    Lynch MR; Carey RJ
    Behav Brain Res; 1989 Feb; 32(1):69-74. PubMed ID: 2495013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Midbrain dopamine neurons: differential responses to amphetamine isomers.
    Browder S; German DC; Shore PA
    Brain Res; 1981 Mar; 207(2):333-42. PubMed ID: 7470912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.